NCT06188741View on ClinicalTrials.gov

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

September 1, 2031

Study Completion Date

September 1, 2032

Conditions
Neurofibromatosis 1Plexiform Neurofibroma
Interventions
DRUG

Selumetinib

Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID

Trial Locations (3)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

35233

RECRUITING

Childrens of Alabama, Birmingham

45229-

RECRUITING

Cincinnati Childrens Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Congressionally Directed Medical Research Programs

FED

lead

University of Alabama at Birmingham

OTHER

NCT06188741 - Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | Biotech Hunter | Biotech Hunter